Bridging Genomics and Manufacturing: Middleware Solutions for Personalized Medicine Production

Pharmaceutical companies, faced with stiff competition from the rapid progression of genomic medicine and next-generation sequencing (NGS) technology adoption, are beginning to move from their customary mass manufacturing model to a patient-centric therapeutic model. Customary centralized pharmaceutical manufacturing and supply chains are not suited to manufacture the customized formulations that patientcentric therapies require within clinically relevant time frames. A distributed middleware architecture is used to support the real-time data flows between the genomic sequencing centers and the geographically dispersed pharmaceutical manufacturing sites. Production digital twins are used to manage the production facilities. Digital twins of production facilities know the capabilities, equipment state, regulatory clearances, and queue for processing medical instruments in real time. Smart facility selection algorithms account for the network capacity of the routing path for patient-specific requests. Privacy-preserving computational models such as secure multi-party computation and homomorphic encryption can be used for genomic sequencing scheduling optimization. Event-driven interlinking of manufacturing metadata databases enables constraint-aware distributed scheduling for multi-objective optimization of patient wait time, facility utilization, regulatory compliance, and resource allocation. Discrete-event simulation modeling and piloted implementations show the feasibility of orchestrating secondary therapiesacross regional manufacturing networks, while offering cryptographic guarantees of privacy and regulatory auditability. Keywords: Personalized Medicine Manufacturing, Distributed Middleware Orchestration, Genomic Data Integration, Privacy-Preserving Computation, Digital Twin Architecture.